Appili Therapeutics Inc (APLI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Appili Therapeutics Inc (APLI) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-293.07K ≈ $-212.00K USD) by net assets (CA$-16.38 Million ≈ $-11.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Appili Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Appili Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Appili Therapeutics Inc (APLI) financial obligations for a breakdown of total debt and financial obligations.
Appili Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Appili Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
NASDAQ:CUPR
|
N/A |
|
Mobeus Income And Growth Vct Plc
LSE:MIX
|
-0.004x |
|
OurLiving AB
ST:OURLIV
|
-4.139x |
|
Camellia Plc
LSE:CAM
|
-0.059x |
|
Helios Underwriting PLC
LSE:HUW
|
-0.486x |
|
Alpha Star Acquisition Corp
NASDAQ:ALSA
|
0.087x |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
N/A |
|
Fintech Chain Ltd
AU:FTC
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Appili Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Appili Therapeutics Inc (APLI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$-13.40 Million ≈ $-9.69 Million |
CA$868.82K ≈ $628.49K |
-0.065x | -128.75% |
| 2024-03-31 | CA$-10.92 Million ≈ $-7.90 Million |
CA$-2.46 Million ≈ $-1.78 Million |
0.226x | -83.48% |
| 2023-03-31 | CA$-7.40 Million ≈ $-5.35 Million |
CA$-10.10 Million ≈ $-7.30 Million |
1.365x | -76.60% |
| 2022-03-31 | CA$-3.27 Million ≈ $-2.37 Million |
CA$-19.08 Million ≈ $-13.80 Million |
5.834x | +749.77% |
| 2021-03-31 | CA$12.75 Million ≈ $9.23 Million |
CA$-11.45 Million ≈ $-8.28 Million |
-0.898x | -86.42% |
| 2020-03-31 | CA$8.85 Million ≈ $6.40 Million |
CA$-4.26 Million ≈ $-3.08 Million |
-0.482x | +38.42% |
| 2019-03-31 | CA$4.42 Million ≈ $3.20 Million |
CA$-3.46 Million ≈ $-2.50 Million |
-0.782x | -15.22% |
| 2018-03-31 | CA$4.87 Million ≈ $3.52 Million |
CA$-3.30 Million ≈ $-2.39 Million |
-0.679x | +56.34% |
| 2017-03-31 | CA$1.37 Million ≈ $994.41K |
CA$-2.14 Million ≈ $-1.55 Million |
-1.555x | -- |
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more